B
Biocon Ltd
Pharmaceuticals
₹ 397.30 -0.85 (-0.21%)
₹ 397.30 -0.85 (-0.21%)
- NSE
- BSE
Overview
- BSE Code 532523
- NSE Symbol BIOCON
- ISIN Demat INE376G01013
- Book Value (₹) 119.85
- Face Value (₹) 5.00
- Market Cap (₹ Cr.) 53,331.48
- P/E (TTM) 0.00
- EPS (TTM) 0.37
- Div Yield (%) 0.28
Performance
Today’s Low 394.40
Today’s High 403.00
52W Low 291.00
52W High 406.00
Open 400.00
Prev. Close 398.15
Volume 55,29,147.00
Corporate Actions
Biocon Limited - General Updates
Apr 26, 2025Biocon Limited has informed the Exchange about Company Statement dated April 26, 2025
About Biocon Ltd
Biocon Limited came into existence as in 1978 as Biocon India Private Limited. In 1979, it became the first Indian company to manufacture and export enzymes to the USA and Europe. The company incorporated BCZ (BioChemizyme India) in 1982 to core priority on research and development in relation to enzymes. It enhanced its in-house research programme, based on a proprietary solid substrate fermentation technology, from the pilot to the plant level in 1990.
The company leveraged its technology platform to enter biopharmaceuticals and statins in 1996. In 2004, the company went for an IPO to raise ₹300 crore to fund its huge capital expansion plans. As a result, it was listed on BSE and NSE.
After 4 years, Biocon gained complete control of a 78% stake in German pharmaceutical company AxiCorp GmbH for a consideration of €30 million in 2008. In the same year, it became the 7th largest biotech employer in the world by Med Ad News. In 2013, the company made a strategic entry into into a partnership with Mylan through strategic collaboration for insulin products. Syngene (CRO Arm of Biocon) got listed on BSE and NSE in 2015.
In 2023, Kiran Mazumdar-Shaw was honoured with the G20 Healthcare Commitment Awards 2023 at the 21st Asian Business and Social Forum 2023 and The Healthier India Conclave 2023.
Business Segments
- Generics:The organization manufactures and supplies innovative and affordable generic bulk drugs and finished formulations under this segment.
- Biosimilars:The company administers this business through Biocon Biologics Limited (BBL), a leading global biosimilars player with established capabilities in developing, manufacturing and commercialising biosimilars.
- Novel Biologics:It is actively involved in innovating novel assets for autoimmune diseases and cancer. The organization rolled out Nimotuzumab (India’s first indigenously manufactured monoclonal antibody) for head and neck cancer in 2006.
- Research Services:The organization run this enterprise through Syngene, which has established itself as a leading global organization bringing forth integrated discovery research, development and manufacturing services.
Subsidiaries
As of March 31, 2023, the company had 26 subsidiaries and few of the subsidiaries listed below:- Syngene International Limited:It is a subsidiary of Biocon. The company offers services that include integrated drug discovery and development capabilities in chemistry, biology, vivo and vitro pharmacology, etc.
- Syngene USA Inc:It is a wholly owned subsidiary of Syngene, incorporated in 2017. It offers business and sales support services to the operations of Syngene in the USA.
- Syngene Scientific Solutions Limited (SSSL):Itis a wholly owned subsidiary of Syngene. It is engaged in Contract Research and Manufacturing Services (CRAMS) and Clinical research services.
Key Personnel
Kiran Mazumdar-Shaw, Executive Chairperson – Biocon Limited and Biocon Biologics Limited Kiran Mazumdar-Shaw started her journey in 1978 from her garage in India. She is a first-generation entrepreneur and global business leader with an experience of more than 4 decades in biotechnology. She has been chairperson of the Board of Directors since its inception. Corporate Actions In 2019, the company announced a bonus issue of 1:1 with a record date of June 12, 2019. In 2017, Biocon announced a bonus issue of 2:1 with a record date of June 15, 2017. Management Outlook- For the generics segment, the growth drivers include enhanced capacities in its API enterprise, growth in the volume of its base enterprise and traction from its recently launched generic formulation products.
- The priorities for the generics enterprise revolve around increasing the market share in existing products and new product launches, especially in the US.
SWOT Analysis
Strengths- Diversified revenue stream.
- First-mover advantage in the biologics enterprise.
- Lack of technology implementation.
- Rising consumer disposable income.
- International enterprise opportunities.
- Intense competition from peers.
- Changing climate scenario.
| Founded | : 1978 |
| Chairman | : Kiran Mazumdar Shaw |
| Managing Director | : SIDDHARTH MITTAL |
| Address | : 20th KM Hosur Road Hebbagodi, Electronic City P O, Bangalore, Karnataka, 560100, |
| HO Tel | : 91-80-2808 2808/4014 4014 |
Open A Free Demat Account Today
Get StartedDocuments To Be Kept Handy
- PAN Card
- Cancelled Cheque
- Latest 6 month Bank Statement (Only for Derivatives Trading)